Aprea Therapeutics, Inc. Stock-Based Compensation
Aprea Therapeutics, Inc. (APRE) reported Stock-Based Compensation of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-12
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $100.00K, a 0.00% change year-over-year.
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $100.00K, a 32.93% decline year-over-year.
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $100.00K, a 22.17% decline year-over-year.
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $100.00K, a 0.00% change year-over-year.
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2020 was $4.98M, a 270.29% increase from fiscal 2019.
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2019 was $1.35M, a 308.02% increase from fiscal 2018.
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2018 was $329.81K, a 16.60% decline from fiscal 2017.
- Aprea Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2017 was $395.44K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 15 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-08-12 | $200.00K 10-Q · filed 2026-08-12 | ||||||
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-13 | |||||||
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-12 | $200.00K derived: sum of 2 quarters · filed 2026-08-12 | $400.00K 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-12 | $300.00K 10-Q · filed 2026-08-12 | ||||||
| 2025-03-31 | $100.00K 10-Q · filed 2025-05-14 | |||||||
| 2024-09-30 | $149.09K 10-Q · filed 2024-11-07 | $277.58K derived: sum of 2 quarters · filed 2024-11-07 | $400.00K 10-Q · filed 2025-11-12 | $363.41K 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $128.49K 10-Q · filed 2024-08-12 | $200.00K 10-Q · filed 2025-08-12 | $214.32K 10-Q · filed 2024-08-12 | |||||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-14 | $85.83K 10-Q · filed 2024-05-14 | ||||||
| 2023-09-30 | $76.03K 10-Q · filed 2024-11-07 | $345.35K derived: sum of 2 quarters · filed 2024-11-07 | $361.60K 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | $269.32K 10-Q · filed 2024-08-12 | $285.57K 10-Q · filed 2024-08-12 | ||||||
| 2023-03-31 | $16.24K 10-Q · filed 2024-05-14 | |||||||
| 2022-09-30 | $38.24K 10-Q · filed 2023-11-09 | $14.84M derived: sum of 2 quarters · filed 2023-11-09 | $16.90M 10-Q · filed 2023-11-09 | $16.92M 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $14.80M 10-Q · filed 2023-08-10 | $14.80M 10-Q · filed 2022-08-12 | $16.90M 10-Q · filed 2023-08-10 | $16.89M 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $2.10M 10-Q · filed 2023-05-15 | $2.08M 10-Q · filed 2022-05-16 | ||||||
| 2021-09-30 | $2.04M 10-Q · filed 2022-11-09 | $3.90M derived: sum of 2 quarters · filed 2022-11-09 | $5.72M 10-Q · filed 2022-11-09 | $7.15M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $1.86M 10-Q · filed 2022-08-12 | $3.69M 10-Q · filed 2022-08-12 | $5.12M derived: sum of 3 quarters · filed 2022-08-12 | $6.51M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $1.82M 10-Q · filed 2022-05-16 | $3.25M derived: sum of 2 quarters · filed 2022-05-16 | $4.64M derived: sum of 3 quarters · filed 2022-05-16 | $5.90M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $2.82M derived: sum of 2 quarters · filed 2021-11-08 | $4.08M derived: sum of 3 quarters · filed 2021-11-08 | $4.98M 10-K · filed 2021-03-16 | ||||
| 2020-09-30 | $1.39M 10-Q · filed 2021-11-08 | $2.65M derived: sum of 2 quarters · filed 2021-11-08 | $3.55M 10-Q · filed 2021-11-08 | $4.37M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2020-06-30 | $1.26M 10-Q · filed 2021-08-12 | $2.16M 10-Q · filed 2021-08-12 | $2.98M derived: sum of 3 quarters · filed 2021-08-12 | $3.22M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $905.47K 10-Q · filed 2021-05-06 | $1.72M derived: sum of 2 quarters · filed 2021-05-06 | $1.97M derived: sum of 3 quarters · filed 2021-05-06 | $2.15M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $814.59K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.06M derived: sum of 2 quarters · filed 2021-03-16 | $1.25M derived: sum of 3 quarters · filed 2021-03-16 | $1.35M 10-K · filed 2021-03-16 | ||||
| 2019-09-30 | $246.22K 10-Q · filed 2020-11-06 | $433.19K derived: sum of 2 quarters · filed 2020-11-06 | $531.13K 10-Q · filed 2020-11-06 | $611.30K derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-06-30 | $186.96K 10-Q · filed 2020-08-11 | $284.91K 10-Q · filed 2020-08-11 | $365.08K derived: sum of 3 quarters · filed 2021-03-16 | $444.87K derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-03-31 | $97.95K 10-Q · filed 2020-05-15 | $178.12K derived: sum of 2 quarters · filed 2021-03-16 | $257.91K derived: sum of 3 quarters · filed 2021-03-16 | |||||
| 2018-12-31 | $80.17K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $159.96K derived: sum of 2 quarters · filed 2021-03-16 | $329.81K 10-K · filed 2021-03-16 | |||||
| 2018-09-30 | $79.79K 10-Q · filed 2019-11-14 | $249.65K 10-Q · filed 2019-11-14 | ||||||
| 2017-12-31 | $395.44K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |